Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer: A Phase II Trial

NCT06175390 is registered in ClinicalTrials.gov with Institut Curie as lead sponsor.

NCT NCT06175390
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06175390 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer: A Phase II Trial
Lead sponsor
Institut Curie
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 27, 2024
Completion date
February 15, 2029
Enrollment
81 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer